The intersection of artificial intelligence and biotechnology is no longer a futuristic concept; it’s a rapidly unfolding reality. This was the resounding message from “Breakthrough Applications of AI in Biotech,” an insightful event recently hosted by PQE Group at the Cambridge Innovation Center (CIC) in Philadelphia. The discussion, moderated by Chris Frew, Founder of BioBuzz, featured an expert panel that unpacked the current state, challenges, and immense potential of AI in accelerating life-saving therapies to patients, making them “faster, better, less expensive.”
The distinguished panelists included:
- Jared Auclair, Dean, College of Professional Studies, Northeastern University; Director of Bio Innovation
- Irene Rombel, CEO and Co-founder, BioCurie
- Kathleen Brunner, President and CEO, Acumen Analytics
- Michael Phelan, PhD, Associate Director, MPA Quality & Manufacturing, Integral Molecular
The “Breakthrough Applications of AI in Biotech” event served as a powerful reminder that AI’s integration into biotech is a dynamic, evolving process. Success hinges on a proactive and informed strategy that prioritizes data quality, robust validation, continuous monitoring, and the cultivation of a cross-disciplinary workforce. As the FDA continues to embed AI into its regulatory processes, the ability to strategically harness this technology will be paramount for companies striving to bring innovative, life-changing therapies to patients.
Key Takeaways from the Panel Discussion:
The discussion kicked off with a crucial effort to define AI within today’s biotech landscape. Jared Auclair clarified that AI involves computers performing human-like tasks, with the critical distinction of learning and adapting from data. Irene Rombel succinctly added that AI enables tasks to be performed “better than what a human can do.”
The “Garbage In, Garbage Out” Reality and Data Quality
A foundational truth reiterated by the panel was the “garbage in, garbage out” principle, underscoring that the efficacy of AI is directly proportional to the quality of the data it consumes. Kathleen Brunner highlighted a significant hurdle: over 80% of organizational data, often found in unstructured formats like PDFs and lab notebooks, is currently difficult for AI applications to utilize. This necessitates investment in unified digital infrastructures to overcome internal data silos that hinder seamless information flow across the entire product lifecycle, from research and discovery to clinical trials, manufacturing, and commercialization.
Navigating the Evolving Regulatory Landscape for AI
One of the most pressing insights for biotech companies is the rapidly evolving regulatory landscape around AI. Michael Phelan shared updates from the FDA’s Emerging Technology Program—a pilot designed to evaluate and qualify innovative drug development tools, including artificial intelligence. He noted that the FDA is currently focused on clinical applications, such as analyzing outcomes, adverse events, and imaging data, with an emphasis on unbiased, reproducible results and a “human in the loop” approach.
A key development, announced just a week before the event, was the launch of Elsa—a secure, agency-wide generative AI tool now being used to assist in reviewing regulatory submissions like INDs, NDAs, and VLDs. Elsa’s deployment marks a significant shift toward AI-assisted regulation, making it increasingly essential for companies to align their processes with the FDA’s growing use of AI. Experts emphasized the need for validated tools, rigorous uncertainty quantification, continuous model management, and transparent audit trails to ensure reliability and trust in regulated environments.
The Indispensable Role of Human Expertise
Even with the rapid advancements in AI, the panel discussion powerfully emphasized the enduring, and indeed growing, critical role of human expertise.
Jared Auclair highlighted the significant shortage of “cross-trained” professionals—individuals who possess a robust grasp of data, data analytics, and life sciences, noting a daily demand for such rare talent. Kathleen Brunner’s insightful observation resonated deeply: “Artificial intelligence is not going to take your job. The person who knows how to use it is going to take your job.” This sentiment underscores the imperative for continuous education and the development of cross-disciplinary teams that can effectively leverage AI tools while understanding their limitations and potential pitfalls. In essence, while AI offers powerful capabilities, it is the human ability to integrate diverse knowledge sets and skillfully apply these tools that will drive innovation and success.
Where AI Delivers Value and the Promise of Personalized Medicine
While early investments in AI for molecule identification and drug discovery have shown limited returns on investment (ROI) due to the inherent complexity and numerous unknown variables in human biology, the panel agreed that AI offers significant value further down the value chain. Irene Rombel pointed to process development, manufacturing, and regulatory filings as areas where AI can be highly effective due to better-understood variables, leading to more predictive models. Michael Phelan echoed this, noting the FDA’s focus on AI in clinical outcomes and image analysis as areas yielding the most immediate impact.
The promising realm of personalized medicine also featured prominently. Rombel shared a compelling “Philadelphia story” about a personalized gene-editing medicine developed at CHOP for a baby diagnosed with a rare genetic disorder. This groundbreaking collaboration showcased how AI, even for imaging purposes, can accelerate such life-saving breakthroughs, highlighting the potential for AI to aid in tailoring therapies.
Addressing Challenges and Embracing AI: It’s No Longer Optional
Despite the palpable excitement, the panel acknowledged significant challenges. Jared Auclair highlighted the widening gap in regulatory capacity globally, with many developing economies struggling to establish basic regulatory frameworks, let alone adopt cutting-edge AI technologies. Irene Rombel emphasized the critical need to democratize AI tools, making them accessible and affordable worldwide to prevent accentuating existing disparities.
For smaller companies, the perceived cost and complexity of AI implementation can be daunting. However, the expert consensus was clear: engaging with AI is no longer optional. Kathleen Brunner advised that “the bus has left,” urging firms to “get on board.” The panel suggested a stepwise approach, starting with simpler applications like generative AI for documentation and gradually progressing to more complex models for process and decision-making. Indeed, smaller and mid-market companies, with their inherent agility, may be better positioned to leverage AI effectively than larger, slower-to-change organizations.
About PQE Group
PQE Group is a global consultancy serving the life sciences industry, and its story is deeply rooted in the bold vision of its founder and CEO, Gilda D’Incerti. After being fired from her previous job, Gilda didn’t just start over—she started something revolutionary. In 1998, she launched PQE with a clear mission: to create a consulting firm that prioritized ethics, transparency, and impact, while helping pharmaceutical, biotech, and medical device companies navigate the highly complex world of regulatory compliance.
Today, PQE Group operates in over 40 countries with a team of more than 2,000 experts. The company provides a full spectrum of services across the product life cycle—from R&D to post-market surveillance. Their offerings include GxP compliance, quality assurance, qualification and validation, regulatory affairs, clinical auditing, data integrity, cybersecurity, and end-to-end support for regulatory submissions and global market access. PQE is particularly known for its deep expertise in helping companies meet FDA, EMA, and other international regulatory standards, which is critical for bringing safe, effective therapies to market.
Under Gilda’s leadership, PQE has built a reputation not just for technical excellence, but for being a mission-driven organization. The company actively invests in sustainability, corporate social responsibility, and diversity initiatives—especially supporting women returning to work after maternity leave. Gilda’s belief that business success and social impact can coexist has become a cornerstone of PQE’s identity. Her journey from professional setback to global CEO is more than inspiring—it’s the foundation of a company that continues to raise the standard for what life sciences consulting can and should be.
